[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News and Perspectives
January 5, 2005

More Scrutiny for Dietary Supplements?

JAMA. 2005;293(1):27-28. doi:10.1001/jama.293.1.27

In an attempt to tighten the reins over control of dietary supplements, the US Food and Drug Administration (FDA) has announced several regulatory initiatives. The actions come following criticism that the government has reacted too slowly to the dangers posed by supplements such as ephedra and androstenedione, both of which were taken off the market earlier this year.

The new initiatives include a regulatory strategy designed to further implement the Dietary Supplement Health and Education Act of 1994 (DSHEA), an open public meeting, and a draft guidance document for industry. Passage of DSHEA allowed dietary supplements—defined by Congress as products that contain ingredients including vitamins, minerals, herbs or other botanicals, amino acids, and substances such as enzymes, organ tissues, glandulars, and metabolites—to be sold over the counter with little oversight unless the FDA could demonstrate a product posed a clear danger to public health.

First Page Preview View Large
First page PDF preview
First page PDF preview